ExcitePCR to Hold Press Conference in Washington, D.C. on September 18

Share Article

During its Press Conference, ExcitePCR will summarize its multiyear history, showcase its FireflyDX technologies, and release an "ExcitePCR Executive Summary" of a report produced for it by Lawrence Livermore National Laboratory

The company will release details from a Lawrence Livermore National Laboratory Report that states ExcitePCR's FireflyDX automated pathogen detection technologies have no known direct competition.

ExcitePCR™ today announced that it will hold a Press Conference at 10 a.m. on Monday, September 18 at the National Press Club in Washington, D.C.

During its Press Conference, ExcitePCR will

  •      Summarize its multiyear history in designing, developing and producing automated biohazard detection solutions for U.S. governmental agencies and military organizations,
  •     Showcase its forthcoming FireflyDX™ portable, realtime pathogen detection systems, and
  •     Release an ExcitePCR Executive Summary of a report produced for it by Lawrence Livermore National Laboratory.

What:
An ExcitePCR Press Conference on Monday, September 18, 2017, from 10-11 a.m. (ET) will disclose details from a Lawrence Livermore National Laboratory Report prepared for the company that states that ExcitePCR’s FireflyDX automated pathogen detection technologies have no known direct competition. {NOTE: ExcitePCR will release its own Executive Summary of the LLNL Report during the Press Conference.}

During the press conference, ExcitePCR will also provide additional details about its lightweight, bookbag-sized FireflyDX-Portable™, a realtime pathogen detection system designed to enable first responders, medical professionals and food safety workers to accurately obtain on-site results anywhere in the world in less than 30 minutes, including sample preparation time.

Where:    
The ExcitePCR Press Conference will be held at the National Press Club in Washington, D.C. at 529 14th Street NW, Washington, D.C.

When:    
The ExcitePCR Press Conference will be held from 10-11 a.m. (ET) on Monday, September 18, 2017.

Who:    
Representing ExcitePCR at the Press Conference will be

  •     Lyle Probst, President, CEO, and Founder;
  •     Kimothy Smith, Ph.D., Chief Science Officer; and
  •     David Politis, Chief Marketing & Sales Officer.

Journalists & Analysts Who Should Attend:
Journalists and Analysts interested in and/or who cover/report on infectious diseases, pandemics, epidemics, biohazards, pathogenic threats, First Responders, Homeland Security, the military, and/or Polymerase Chain Reaction (PCR), as well as those who follow or have reported on such firms as Theranos, bioMerieux, Thermo Fisher Scientific, are those most likely to appreciate the information that will be shared during ExcitePCR’s September 18th Press Conference.

Why:    
Including its predecessor companies, ExcitePCR has received over $35 million since 2004 from the U.S. Department of Homeland Security (DHS) and other U.S. governmental entities to design, develop and produce rapid pathogen detection solutions. This foundational work has allowed ExcitePCR to produce significant breakthroughs in the world of PCR-based solutions for rapidly and accurately identifying the presence of countless biological threats anywhere in the world, including the typically time-consuming act of sample preparation, all within 30 minutes or less. ExcitePCR has now begun work to commercialize its FireflyDX technologies.

Additional Information:    
Following the Press Conference on September 18, ExcitePCR’s CEO, Lyle Probst, will participate in a prestigious, three-person Panel Discussion that afternoon about current and future advancements in pathogen detection systems hosted by the National Academies of Sciences, Engineering, and Medicine (NAS). This Panel Discussion is part of a two-day, BioWatch Workshop on “Strategies for Effective Biological Detection Systems” hosted by the NAS. Interested parties can learn more about this Panel Discussion here.

About ExcitePCR
ExcitePCR Corporation is developing portable pathogen detection systems based upon superior sample preparation and realtime PCR (Polymerase Chain Reaction) methodologies. Its FireflyDX technologies will deliver rapid automated Point-of-Care/Point-of-Need (POC/PON) sample preparation and highly accurate biohazard identification in a fraction of the time currently possible using existing PCR-based solutions.

Disclaimer: This document may contain research results that are experimental in nature, and neither the United States Government, any agency thereof, Lawrence Livermore National Security, LLC, nor any of its employees makes any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not constitute or imply an endorsement or recommendation by the U.S. Government or Lawrence Livermore National Security, LLC. The views and opinions of authors expressed herein do not necessarily reflect those of the U.S. Government or Lawrence Livermore National Security, LLC and will not be used for advertising or product endorsement purposes.

ExcitePCR, FireflyDX and FireflyDX-Portable are each trademarks of ExcitePCR Corporation. All other trademarks are the property of their respective owners.

# # #

CONTACT: David Politis, dpolitis(at)excitepcr(dot)com, C: 801-556-8184

Share article on social media or email:

View article via:

Pdf Print

Contact Author

David Politis
ExcitePCR
+1 801-556-8184
Email >
Visit website